Celltrion’s CT-P71 receives FDA Fast Track designation for urothelial cancer
Apr 09, 2026
Celltrion said CT-P71 received FDA Fast Track designation for previously treated locally advanced or metastatic urothelial cancer. The ADC candidate is in Phase 1 testing.